Institute of Medical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Tissue Eng Part A. 2013 Jul;19(13-14):1592-600. doi: 10.1089/ten.TEA.2012.0394. Epub 2013 Apr 15.
Novel tissue-engineering approaches for cardiovascular matrices based on xenogeneic extracellular matrix protein (ECMp) constituents require a detailed evaluation of their interaction with essential immune cell subsets playing a role in innate or adaptive immunity. Therefore, in this study, the effects of xenogeneic (porcine, bovine) collagen type I and elastin as the two main components of the heart valve ECM were analyzed in comparison to their human equivalents. First, their potential to induce maturation and cytokine secretion of human dendritic cells (DC) was tested by flow cytometry. Second, the influence on proliferation and cytokine release of purified human B and T cells was measured. We could demonstrate that xenogeneic collagen type I and elastin are not able to trigger the maturation of DC as verified by the lack of CD83 induction accompanied by a low tumor necrosis factor-α release. Moreover, both ECMp showed no effect on the proliferation and the interleukin-6 release of either unstimulated or prestimulated B cells. Additionally, anti-CD3-induced purified T cell proliferation and secretion of cytokines was not affected. All in vitro data verify the low immunogenicity of porcine and bovine collagen type I and elastin and favor their suitability for tissue-engineered scaffolds.
基于异种细胞外基质蛋白 (ECMp) 成分的新型心血管基质组织工程方法需要详细评估其与在先天或适应性免疫中发挥作用的基本免疫细胞亚群的相互作用。因此,在这项研究中,分析了异种(猪、牛)胶原蛋白 I 和弹性蛋白作为心脏瓣膜 ECM 的两个主要成分,以比较它们与人类等同物的相互作用。首先,通过流式细胞术测试它们诱导人树突状细胞 (DC) 成熟和细胞因子分泌的潜力。其次,测量了它们对纯化的人 B 和 T 细胞增殖和细胞因子释放的影响。我们可以证明异种胶原蛋白 I 和弹性蛋白不能触发 DC 的成熟,这可以通过缺乏伴随低肿瘤坏死因子-α释放的 CD83 诱导来验证。此外,两种 ECMp 对未刺激或预刺激 B 细胞的增殖和白细胞介素-6 释放均没有影响。此外,抗 CD3 诱导的纯化 T 细胞增殖和细胞因子分泌不受影响。所有体外数据均证实了猪和牛胶原蛋白 I 和弹性蛋白的低免疫原性,并有利于它们在组织工程支架中的适用性。